Molecular target based combinational therapeutic approaches in thyroid cancer

Journal of Translational Medicine

Raj K Tiwari²  Jan Geliebter²  Stimson P Schantz¹  Ameet Kamat¹  Andrea L George²  Robert Suriano²  Shilpi Rajoria² 

[1] Department of Otolaryngology, New York Eye and Ear Infirmary New York, New York, 10003, USA;Department of Microbiology and Immunology, New York Medical College, Valhalla, New York, 10595, USA

关键词: 3,3′-diindolylmethane;    Vascular Endothelial Growth Factor;    Angiogenesis;    Estrogen;    Thyroid Cancer;   

Others  :  1206000
DOI  :  10.1186/1479-5876-10-81

 received in 2011-12-01, accepted in 2012-04-10,  发布年份 2012

【 摘 要 】

Background

Thyroid cancer, as with other types of cancer, is dependent on angiogenesis for its continued growth and development. Interestingly, estrogen has been shown to contribute to thyroid cancer aggressiveness in vitro, which is in full support of the observed increased incidence of thyroid cancer in women over men. Provided that estrogen has been observed to contribute to increased angiogenesis of estrogen responsive breast cancer, it is conceivable to speculate that estrogen also contributes to angiogenesis of estrogen responsive thyroid cancer.

Methods

In this study, three human thyroid cancer cells (B-CPAP, CGTH-W-1, ML-1) were treated with estrogen alone or estrogen and anti-estrogens (fulvestrant and 3,3′-diindolylmethane, a natural dietary compound) for 24 hours. The cell culture media was then added to human umbilical vein endothelial cell (HUVECs) and assayed for angiogenesis associated events. Vascular endothelial growth factor (VEGF) levels were also quantified in the conditioned media so as to evaluate if it is a key player involved in these observations.

Results

Conditioned medium from estrogen treated thyroid cancer cells enhanced phenotypical changes (proliferation, migration and tubulogenesis) of endothelial cells typically observed during angiogenesis. These phenotypic changes observed in HUVECs were determined to be modulated by estrogen induced secretion of VEGF by the cancer cells. Lastly, we show that VEGF secretion was inhibited by the anti-estrogens, fulvestrant and 3,3′-diindolylmethane, which resulted in diminished angiogenesis associated events in HUVECs.

Conclusion

Our data establishes estrogen as being a key regulator of VEGF secretion/expression in thyroid cells which enhances the process of angiogenesis in thyroid cancer. These findings also suggest the clinical utility of anti-estrogens as anti-angiogenic compounds to be used as a therapeutic means to treat thyroid cancer. We also observed that 3,3′-diindolylmethane is a promising naturally occurring anti-estrogen which can be used as a part of therapeutic regimen to treat thyroid cancer.

【 授权许可】

   
2012 rajoria et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Ramsden JD: Angiogenesis in the thyroid gland. J Endocrinol 2000, 166:475-480.
• [2]Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
• [3]Segal K, Shpitzer T, Feinmesser M, Stern Y, Feinmesser R: Angiogenesis in follicular tumors of the thyroid. J Surg Oncol 1996, 63:95-98.
• [4]Ishiwata T, Iino Y, Takei H, Oyama T, Morishita Y: Tumor angiogenesis as an independent prognostic indicator in human papillary thyroid carcinoma. Oncol Rep 1998, 5:1343-1348.
• [5]Bergers G, Benjamin LE: Angiogenesis: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
• [6]Delli Carpini J, Karam AK, Montgomery L: Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 2010, 13:43-58.
• [7]Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027.
• [8]Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
• [9]Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S: Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol 2007, 88:271-277.
• [10]Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991, 266:11947-11954.
• [11]Robinson CJ, Stringer SE: The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001, 114:853-865.
• [12]Cébe-Suarez S, Zehnder-Fjällman A, Ballmer-Hofer K: The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci 2006, 63:601-615.
• [13]Soh E, Duh Q, Sobhi S, Young D, Epstein H, Wong M, Garcia Y, Min Y, Grossman R, Siperstein A, Clark O: Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 1997, 82:3741-3747.
• [14]Losordo DW, Isner JM: Estrogen and angiogenesis: A review. Arterioscler Thromb Vasc Biol 2001, 21:6-12.
• [15]Suriano R, Chaudhuri D, Johnson RS, Lambers E, Ashok BT, Kishore R, Tiwari RK: 17β-Estradiol Mobilizes Bone marrow–Derived Endothelial Progenitor Cells to Tumors. Cancer Res 2008, 68:6038-6042.
• [16]Chen GG, Vlantis AC, Zeng Q, van Hasselt CA: Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. Curr Cancer Drug Targets 2008, 8:367-377.
• [17]Rajoria S, Suriano R, George A, Shanmugam A, Schantz SP, Geliebter J, Tiwari RK: Estrogen induced metastatic modulators MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in thyroid cancer. PLoS One 2011, 18:6(1).
• [18]Gialeli C, Theocharis AD, Karamanos NK: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011, 278:16-27.
• [19]Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH: Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-B downstream target genes MMP-9 & uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 2007, 67:3310-3319.
• [20]Rahman KM, Ali S, Aboukameel A, Sarkar SH, Wang Z, Philip PA, Sakr WA, Raz A: Inactivation of NF-B by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther 2007, 6:2757-2765.
• [21]Rajoria S, Suriano R, Parmar SP, Wilson LW, Megwalu U, Moscatello A, Bradlow HL, Sepkovic DW, Geliebter J, Schantz SP, Tiwari RK: Pilot study: 3,3’-diindolylmethane (DIM) modulates estrogen metabolism in patients with thyroid proliferative disease. Thyroid 2011, 21:299-304.
• [22]Benton G, Kleinman HK, George J, Arnaoutova I: Multiple uses of basement membrane-like matrix (BME/Matrigel) in vitro and in vivo with cancer cells. Int J Cancer 2011, 128:1751-1757.
• [23]Fang D, Xiao-qin H: Effect of endothelial progenitor cells in neovascularization and their application in tumor therapy. Chin Med J 2010, 123:2454-2460.
• [24]Coomber BL, Yu JL, Fathers KE, Plumb C, Rak JW: Angiogenesis and the role of epigenetics in metastasis. Clin Exp Metastasis 2003, 20:215-227.
• [25]George AL, Prakash PB, Rajoria S, Suriano R, Shanmugam A, Mittelman A, Tiwari RK: Endothelial progenitor cell biology in disease and tissue regeneration. J Hematol Oncol 2011, 4:24. BioMed Central Full Text
• [26]Rajoria S, Suriano R, Shanmugam A, Wilson YL, Schantz SP, Geliebter J, Tiwari RK: Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid 2010, 20:33-41.
• [27]Friedl P, Wolf K: Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res 2008, 68:7247-9.
• [28]Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2:737-744.
• [29]Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML: Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 2001, 98:12485-12490.
• [30]Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML: Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005, 169:681-691.
• [31]Mira E, Lacalle RA, Buesa JM, de Buitrago GG, Jiménez-Baranda S, Gómez-Moutón C, Martínez-A C, Mañes S: Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. J Cell Sci 2004, 117:1847-1857.